



7-19-01

JB YCT

618 Rec'd PCT/PTO 18 JUL 2001

FORM PTO-1300 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 65558/JPW
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/889821
INTERNATIONAL APPLICATION NO. PCT/IL00/00029	INTERNATIONAL FILING DATE 16 January 2000	PRIORITY DATE CLAIMED 18 January 1999	
TITLE OF INVENTION An Expression Silencing System And Different Uses Thereof			
APPLICANT(S) FOR DO/EO/US <u>Ilan Sela and Sylvia Zeitoune-Simovich</u>			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> have been communicated by the International Bureau. (Courtesy copy of Preliminary Examination report with Amendment enclosed)</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input checked="" type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information:</p> <p>Courtesy copy of the PCT Request, Notice Informing Applicant of the Communication of the International Application to the designated offices, PCT Demand, International Search Report, Express Mail Certificate of Mailing bearing Label No. EL 066 381 208 US dated July 18, 2001.</p>			

APPLICATION NO. (known) (see 37 CFR 1.5) 09/889821		INTERNATIONAL APPLICATION NO. PCT/IL00/00029		ATTORNEY'S DOCKET NUMBER 65558/JPW	
--	--	---	--	---------------------------------------	--

21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
				\$ 860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	52 - 20 =	32	x \$18.00	\$ 546.00	
Independent claims	8 - 3 =	5	x \$80.00	\$ 400.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$270.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 2076.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 1038.00	
SUBTOTAL =				\$ 1038.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 1038.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 0.00	
TOTAL FEES ENCLOSED =				\$ 1038.00	
				Amount to be refunded:	\$
				charged:	\$

a. ☒ A check in the amount of \$ 1038.00 to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
 overpayment to Deposit Account No. 03-3125. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card
 information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
 John P. White, Esq.
 Registration No. 28,678
 Cooper & Dunham LLP
 1185 Avenue of the Americas
 New York, NY 10036


 SIGNATURE
 Gary J. Gershek
 NAME
 39,992
 REGISTRATION NUMBER

AN EXPRESSION SILENCING SYSTEM AND DIFFERENT USES THEREOF

FIELD OF THE INVENTION

The present invention relates to an expression-silencing system which is capable, upon introduction thereof into a selected cell, of rendering the expression, at the RNA level, of a target sequence in said cell, in a tissue or organ regenerated therefrom or in a progeny thereof, substantially silenced. The invention also concerns the different uses of the expression-silencing system of the invention.

BACKGROUND OF THE INVENTION

There have been some attempts by scientists to increase expression levels of transgenes in transgenic animals and plants by the introduction of a bacteriophage T7 polymerase/T7 promoter (T7-pol/pT7) system therein. T7 RNA polymerase (T7-pol) is a single polypeptide of ~98 kDa which specifically recognized the short viral promoter pT7 [Dunn J.J. *et al.* J. Mol. Biol. 166:477-535 (1983); Moffatt B.A. *et al.* J. Mol. Biol. 173:265-269 (1984)]. T7-pol does not require auxiliary proteins for transcription [Chamberlin M., and Ryan T. The Enzymes Ed. Boyer P.D. Academic Press N.Y 15:87-108 (1982)] and recognizes a single (albeit not stringent) terminator.

It was suggested that any gene placed under the control of the T7 promoter will be specifically and strongly transcribed by a cloned T7 RNA polymerase, which was proven to be successful in bacteria [Tabor S., and Richardson C., Proc. Natl. Acad. Sci USA 82:1074-1078 (1985); Studier F.W., and Moffatt, B.A., J. Mol. Biol. 189:113-130 (1986)], and somewhat successful in animal cells [Fuerst T.R., *et al.* Proc. Natl. Acad. Sci. USA 83:8122-8126 (1986); Fuerst T.R., *et al.* Mol. Cell. Biol. 7:2538-2544 (1987)] Dunn J.J., *et al.* Gene 68:259-266 (1988); Lieber, A., *et al.* Nucl. Acids Res. 17:8485-8493 (1989); Moss, B., *et al.* Nature 348:91-92 (1990)].

The situation in plants is more vague. The expression of T7-pol in tobacco protoplasts and the NLS-direction of the expressed enzyme to the nucleus has been reported [Lassner M.W *et al.* Plant Mol. Biol. 17:229-234 (1991)]. In addition, the expression of either T7-pol or a

reporter gene driven by the T7-pol/pT7 system in plants was described [Caviedes, M.A., *et al.*, Abstract #479 of the 4th Intl Congress of Plant Mol. Biol (1994); Tuttle A., *et al.*, Abstract #478 of the 4th Intl Congress of Plant Mol. Biol (1994); Weschke W., Abstract #480 of the 4th Intl Congress of Plant Mol. Biol (1994)]. A more successful T7-pol/pT7 expression system was described [Tuttle, A. *et al.*, Abstracts of the 4th Int. Congress of Plant Mol Biol #478 (1994)] in which T7-pol expressed in tobacco but targeted to the protoplast, directed expression of GUS. A T7-derived system which promotes expression in plants was also described in the course of a novel method to produce hybrid seeds [U.S. Patent No. 5,659,124] and in plastids which may be considered as prokaryotic cells [McBride, K.E. *et al.*, Proc. Natl. Acad. Sci. USA 91:7301-7305 (1994); U.S. Patent 5,545,817].

Gene silencing in transgenic plants is a documented phenomenon, which relates to the introduction of a foreign gene into a cell thereby inducing its silencing, rather than its expression [Cox K.H., and Goldberg R.B. in Plant Molecular Biology, A Practical Approach (Shaw, C.H., ed), Washington DC, IRL Press, pp.1-35 (1988); Baulcombe D.C., and English J.J., Curr. Opin. Biotechnol. 7:173-180 (1996); Meyer P., and Saedler, H., Annu. Rev. Plant Physiol. Plant Mol. Biol. 47:23-48 (1996); Stam M., *et al.*, Ann. Bot 79:3-12 (1997)]. In general, the insertion of a particular gene into a plant may cause the silencing of homologous native or transgenic genes, which is referred to as "co-suppression" [Depicker A., *et al.*, Curr. Opin. Cell Biol 9:373-382 (1997); Matzke M.A., *et al.*, EMBO J. 8:643-649 (1989); Matzke M.A., *et al.*, Mol. Gen. Genet. 238: 379-386 (1993); Napoli C., *et al.*, Plant Cell 2:279-289 (1990)]. Co-suppression may also be caused by the introduction of homologous RNAs into the cells, such as viral RNAs [Lindbo J.A., *et al.*, Plant Cell 5:1749-1759 (1993); Mueller E., *et al.*, Plant J. 7:1001-1013 (1995)].

Silencing may occur at the transcriptional level, i.e. inhibition of transcription [Flavell R.B. Proc. Natl. Acad. Sci. USA 91:3490-3496 (1994); Matzke M.A. *et al.* in Homologous Recombination and Gene Silencing in Plants Ed. Paszkowski J. Kluwer Academic Publishers, Dordrecht 271-307] or post-transcriptionally [Van Blokland R. *et al.*, Plant J. 6:861-877 (1994); Boerjan W., *et al.*, Plant Cell 6:1401-1414 (1994); De Carvalho-Niebel F., *et al.*, Plant Cell 7:347-358 (1995)]. It has been suggested that silencing at the

09889821-120301

post-transcriptional level is caused by degradation of the primary transcript of the expressed gene, thus no mRNA and no protein will be found in the cytoplasm [Tanzar M.M., *et al.* Plant Cell 9:1411-1423 (1997)]. Furthermore, silencing-triggering mechanisms involving the sensing of RNA levels [Goodwin J., *et al.* Plant Cell 8:95-105 (1996); Smith C.J.S., *et al.*, Mol. Gen. Genet. 224:477-481 (1990); Metzlaff M., *et al.* Cell 88:845-854 (1997)] or ectopic pairing of homologous DNA sequences [Baulcombe D.C., and English J.I., Curr. Opin. Biotechnol. 7:173-180 (1996); Matzke M.A., Dev. Genet 11: 214-223 (1990)] have also been suggested. Plant cells which have been silenced for a certain viral transgen and thus became resistant to virus infection due to the specific degradation of viral sequences have also been described [Lindbo J.A., *et al.* (1993) *ibid.*; Goodwin J., *et al.* (1996) *ibid.*].

SUMMARY OF THE INVENTION

The present invention relates to an expression-silencing system comprising:- (a) a first DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or to a functional equivalent or fragment thereof, which sequence carries an NLS sequence, the construct further comprising at least one promoter and at least one terminator sequence operably linked to said T7-pol; (b) a second DNA construct comprising a T7 promoter sequence (pT7) or a functional fragment thereof, at least one targeting sequence downstream to said pT7 and at least one 3' non-translated terminator sequence operably linked to said targeting sequence; which system is capable, upon introduction thereof into a cell, of rendering the expression at the RNA level of a target sequence in said cell, in a tissue or organ regenerated from said cell, or in a progeny thereof, substantially silenced, by causing the substantial disappearance of the RNA or RNA transcript carrying said sequence or a functional part thereof.

In the same aspect, the invention relates to an expression-silencing system comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, the construct further comprising at least one promoter and at least one terminator sequence operably linked to said T7-pol, a T7 promoter (pT7) or a functional equivalent or fragment thereof, at least one targeting sequence downstream to said the pT7, and at least one

additional terminator sequence operably linked to said nucleic acid sequence of interest, said system being capable, upon introduction thereof into a cell, of rendering the expression at the RNA level of a target sequence in said cell, in a tissue or organ regenerated from said cell, or in a progeny thereof, substantially silenced, by causing the substantial disappearance of the RNA or RNA transcript carrying said sequence.

In a second aspect, the invention relates to a process for the transformation of a plant with a gene-silencing system, which process comprises: (a) transforming plant cells with the expression-silencing system of the invention; (b) selecting the plant cells transformed with at least one DNA construct according to (a) and regenerating said selected cells to provide a differentiated flowering plant; and (c) hybridizing a plant transformed with said first DNA construct with a plant transformed with said second DNA construct, which first plant and second plant are obtained in (b), said hybridization thus providing a double-transformed plant in which the expression of a target sequence is substantially suppressed.

Further, the invention relates to a method for producing a transgenic plant carrying a substantially silent target sequence, by hybridizing a plant carrying and expressing said target sequence with a transformed plant obtained by the process of the invention.

Still further, the invention relates to a method for producing a transgenic plant carrying a substantially silent target sequence, by grafting a plant, or parts thereof, carrying and expressing said silent target sequence on a transformed plant obtained by the process of the invention.

Yet further, the invention relates to a method of silencing the expression of a target sequence within the genome of a plant or within the genome of a plant-infecting pathogen, which method comprises the steps of: (a) providing a first plant capable of regenerating; (b) hybridizing said first plant with a second plant transformed with the expression-silencing system of the invention; and (c) selecting those plants obtained by the hybridization of step (b), in which the expression of said target sequence is substantially silenced.

Finally, the invention relates to a method of identifying a nucleic acid of interest within the genome of a plant, wherein the nucleic acid of interest encodes a pre-defined plant

Experiment 1		Experiment 2		Experiment 3		Experiment 4		Experiment 5		Experiment 6		Experiment 7		Experiment 8		Experiment 9		Experiment 10		Experiment 11		Experiment 12		Experiment 13		Experiment 14		Experiment 15		Experiment 16		Experiment 17		Experiment 18		Experiment 19		Experiment 20		Experiment 21		Experiment 22		Experiment 23		Experiment 24		Experiment 25		Experiment 26		Experiment 27		Experiment 28		Experiment 29		Experiment 30		Experiment 31		Experiment 32		Experiment 33		Experiment 34		Experiment 35		Experiment 36		Experiment 37		Experiment 38		Experiment 39		Experiment 40		Experiment 41		Experiment 42		Experiment 43		Experiment 44		Experiment 45		Experiment 46		Experiment 47		Experiment 48		Experiment 49		Experiment 50		Experiment 51		Experiment 52		Experiment 53		Experiment 54		Experiment 55		Experiment 56		Experiment 57		Experiment 58		Experiment 59		Experiment 60		Experiment 61		Experiment 62		Experiment 63		Experiment 64		Experiment 65		Experiment 66		Experiment 67		Experiment 68		Experiment 69		Experiment 70		Experiment 71		Experiment 72		Experiment 73		Experiment 74		Experiment 75		Experiment 76		Experiment 77		Experiment 78		Experiment 79		Experiment 80		Experiment 81		Experiment 82		Experiment 83		Experiment 84		Experiment 85		Experiment 86		Experiment 87		Experiment 88		Experiment 89		Experiment 90		Experiment 91		Experiment 92		Experiment 93		Experiment 94		Experiment 95		Experiment 96		Experiment 97		Experiment 98		Experiment 99		Experiment 100	
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100																																																																																																				

BRIEF DESCRIPTION OF THE FIGURES

Figure 1A-1C *Schematic representation of the various constructs introduced into plants.*

Fig. 1A represents the p35S-GUS construct, Fig. 1B represents the p35S-T7pol construct and Fig. 1C pT7-GUS construct.

Figure 2 *Western blot analysis for the expression of T7 RNA polymerase.*

This figure represents the Western blot analysis for the expression of T7-pol. Lane 1 indicates protein extract from a non-transformed plant. Lanes 2 to 7 indicate extracts from various double-transformed plants. Lane 8 represents a commercial T7 RNA polymerase.

Figure 3A-3B *Nuclear run-on transcription assay of p35S-GUS and p35S-T7pol/pT7-GUS plants.*

Fig. 3A. Transcripts from p35S-GUS nuclei served as a probe. Fig. 3B. Transcripts from p35S-T7pol/pT7-GUS nuclei served as probes. The various membrane "slots" contain plasmids carrying portions of the following cDNA sequences: GUS, the nuclear subunit of rubisco (Rub), actin (Act), NPTII (Km), T7-pol (T7 RNAP), ubiquitin (Ubiq) and the irrelevant plasmid Bluescript (B.S.). Empty slots are indicated by (-).

Figure 4A-4B *RNase protection assay.*

Fig. 4A shows RNase protection assay with a T7-pol probe, presented by the two left lanes and RNase protection with a GUS probe presented by the two right lanes. Fig. 4B shows the RNase protection assay with an actin probe. 35S-GUS designates RNA extracted from p35S-GUS-carrying plants, whereas, T7-GUS designates RNA extracted from plants carrying p35S-T7-pol/pT7-GUS. The arrows indicate the expected positions of GUS, T7-pol and actin.

05669851 420301
PCT/IL00/00029

DETAILED DESCRIPTION OF THE INVENTION

In an attempt to construct a "super-expressing" transgenic plant, by transforming tobacco plants with the T7pol/pT7 system, known to increase expression levels in bacteria and, to some extent, in animal cells, the inventors have surprisingly found that plants transformed with the enzyme T7-pol under the control of the constitutive promoter CaMV-35S (p35S), as well as with a reporter gene (GUS) placed under the control of the pT7, were silenced in respect of GUS expression although sufficiently expressing T7-pol.

Thus, the present invention relates to an expression-silencing system comprising: a first DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or to a functional equivalent or fragment thereof which sequence carries an NLS sequence, the first construct further comprising at least one promoter and at least one terminator sequence operably linked to the T7-pol; and a second DNA construct comprising a T7 promoter sequence (pT7) or a functional fragment thereof, at least one targeting sequence downstream to said pT7 and at least one 3' non-translated terminator sequence operably linked to the targeting sequence; which system is capable, upon introduction thereof into a cell, of rendering the expression at the RNA level of a target sequence in said cell, in a tissue or organ regenerated from said cell or progenies thereof, substantially silenced, which silencing is caused by the substantial disappearance of the RNA or RNA transcript carrying said sequence or a part thereof.

Alternatively, the expression-silencing system of the invention may comprise a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, the system further comprising at least one promoter and at least one terminator sequence operably linked to said T7-pol, a T7 promoter (pT7) or a functional equivalent or fragment thereof, at least one targeting sequence downstream to the pT7, and at least one additional terminator sequence operably linked to said nucleic acid sequence of interest, said system being capable, upon introduction thereof into a cell, of rendering the expression at the RNA level of a target sequence in said cell, in a tissue or organ regenerated from said cell, or in progenies thereof, substantially silenced, by causing the substantial disappearance of the RNA or of an RNA transcript carrying said sequence.

By the term 'functional equivalent/analogue/fragment thereof' is meant any variant of the nucleic acid sequence which retains the biological function of the peptide, protein or protein product transcribed therefrom or any variant of the protein or peptide itself which retain their biological function. Such variants may include modifications, mutations, deletions replacements and/or insertions within the naturally occurring sequence.

The term 'targeting sequence' for purposes defined herein refers to any exogenous sequence which is introduced into a selected cell by means known to the man of the art, such as by employing the expression-silencing system defined herein. Exogenous nucleic acid sequences according to the invention can possess sequences identical or substantially homologous to an endogenous sequence/s or to a part thereof which endogenous sequence/s are present in the cell prior to introduction of said system into said cell. Yet, the exogenous nucleic acid sequence can possess sequences identical or substantially homologous to a pathogenic nucleic acid sequence present in said cell through infection thereof by a pathogen. Naturally, the expression-silencing system of the invention may contain one or more targeting sequences.

The targeting sequences according to the invention are those which permit integration into the genome of the selected cell containing the target gene of interest or into any other nucleic acid sequence present in said cell either prior to introduction of the system of the invention into the cell or as a result of a later infection. Such sequences include those encoding a pathogenic product (e.g. a protein or a peptide), irrespective of whether the pathogenic genome will constitute an integral part of the genome of the cells.

The targeting sequences may be a coding or a non-coding nucleic acid sequence either lying upstream of the transcriptional start site, within the primary transcript, or downstream of the transcriptional stop site of the nucleic acid of interest (target sequence), or the targeting sequence may be any sequence present in the cell through a previous modification. Thus, the targeting sequence or sequences according to the invention may, independently, correspond to the sequence within a gene of interest (such as, the sequences of an exon and/or intron), immediately adjacent to a gene of interest (i.e., with no additional nucleotides between the targeting sequence and the coding region of the gene of interest), upstream gene of interest (such as the sequences of the upstream non-coding

TOE021-12266850

region or promoter sequences), or upstream of and at a distance from the gene (such as, sequences upstream of the promoter sequences).

By the term 'target sequence' is meant any sequence, the suppression of expression of which is desired. The sequence may be endogenous or it may be a sequence of an infecting pathogen. Preferably, the selected cell in which the expression at the RNA level is substantially silenced is any eukaryotic or prokaryotic cell such as a plant cell, a mammalian cell, bacteria, yeast, their pathogens or any suitable tissue culture cells.

By the term 'regenerated tissue or organ' is meant any differentiated tissue or organ regenerated from the cell into which the system of the invention was introduced. One example for a regenerated organ according to the invention is a differentiated flowering plant regenerated from a plant cell into which the silencing system of the invention was introduced.

The silencing of expression by the system of the invention occurs at the RNA level as indicated by the disappearance of the RNA carrying the target sequence, a part thereof or a sequence corresponding thereto. A specific example for such disappearance may be seen in Figs. 3 and 4, which show that although the GUS gene is transcribed, no GUSmRNA is detected. The RNA according to the invention can be any RNA sequence, either a coding or a non-coding one or it may be a transcript of an RNA or DNA coding or non-coding sequences.

In particular, the target sequence according to the invention corresponds to:- (a) a gene encoding a protein or a peptide product, the silencing of which is desired; (b) a non-coding nucleic acid sequence, which, under normal conditions, promotes the expression of an essential coding sequence; (c) a nucleic acid sequence which corresponds to (a) or to (b) or to a fragment thereof, within the scope of degeneracy of the genetic code; or (d) a nucleic acid sequence which hybridizes with the sequence according to (a), to (b), or to (c) or with fragments thereof, which hybridization is carried out under conditions which allow such hybridization to occur. The conditions for hybridization vary and include, for example, hybridization at about 50°C in a solution containing 0.9 M of a suitable salt, such as NaCl.

In case the selected cell is a plant cell, the target gene may encode an expressible plant protein or peptide or an expressible protein or peptide product of a plant pathogen.

As indicated above, a particular embodiment of the first and second DNA constructs of the invention is shown in Figures 1A and 1B, respectively. As may be understood from the figures, the different constituents comprising each construct are linked in a predefined order to enable the efficient silencing of the target gene in the selected cell, upon introduction of the system thereto.

According to a second aspect, the invention relates to a process for the transformation of a plant with a gene-silencing system which process comprises the steps of:- (a) transforming plant cells with:- (i) a first DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof, at least one plant promoter and at least one plant terminator sequence operably linked to said T7-pol; and with (ii) a second DNA construct comprising a T7 promoter sequence or a functional fragment thereof, a targeting sequence downstream to the T7 promoter, and at least one 3' non-translated terminator sequence operably linked to the targeting sequence, said construct optionally further comprising other additional regulatory elements operably linked to the targeting sequence. The process further comprises the steps of (b) selecting the plant cells transformed with at least one DNA construct according to (a) and regenerating said selected cells to provide a differentiated flowering plant; and (c) hybridizing a plant transformed with said first DNA construct with a plant transformed with said second DNA construct, which first plant and second plant are obtained in (b), the hybridization thus provides a double-transformed plant wherein the expression of a target sequence is substantially suppressed. Evidently, cells transformed with both constructs at a single process stage may be utilized for further hybridizations as described herein after.

Within the same aspect, the invention also concerns to a process for the transformation of plant with a gene-silencing system, which process comprises the steps of:- (a) transforming plant cells with a DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, the construct further comprising at least one plant promoter sequence and at least one plant terminator sequence operably linked to the polymerase gene, a T7 promoter sequence (pT7) or a functional fragment thereof, a targeting sequence downstream to said pT7, and at least one additional terminator

sequence operably linked to said targeting sequence, which DNA construct is capable, upon transformation thereof into a plant, of rendering the expression of a target sequence in said plant or in its progeny, substantially silenced; (b) selecting plant cells transformed with said DNA construct according to (a) and regenerating said selected cells to provide such differentiated flowering plant.

According to this process the targeting sequence substantially corresponds to the target sequence or to a fragment thereof. In addition, the target sequence according to the process disclosed herein corresponds to:- (a) a gene encoding a protein or a peptide product, the silencing of which is desired; (b) a non-coding nucleic acid sequence, which, under normal conditions, promote the expression of an essential coding sequence; (c) a nucleic acid sequence which corresponds to (a) or to (b) or to a fragment thereof, within the scope of degeneracy of the genetic code; or (d) a nucleic acid sequence which hybridizes with the sequence according to (a), to (b), or to (c) or with fragments thereof, which hybridization is carried out under conditions which allow such hybridization to occur. Such hybridization conditions vary and include, *inter alia*, hybridization at 50°C in a suitable electrolyte, such as NaCl, solution (0.9M).

As may be seen in the following Examples, upon introduction of the expression-silencing system of the invention (Figs. 1A and 1B), containing as the target gene the sequence encoding the GUS protein, into a plant cell that was previously engineered to express this bacterial protein, the expression of the gene was suppressed.

In a third aspect, the invention relates to a method for producing a transgenic plant carrying a substantially silent target sequence, by hybridizing a plant carrying and expressing said target sequence with a transformed plant obtained by the process of the invention.

In yet another aspect, the invention relates to a method for producing a transgenic plant carrying a substantially silent target sequence, by grafting a plant, or parts thereof, carrying and expressing said silent target sequence on a transformed plant obtained by the process of the invention, as shown in Example 4.

Transgenic plants or progenies thereof obtained by the above disclosed methods, in which the expression of a predefined target sequence is substantially suppressed as the result of said hybridization, are also within the scope of the invention.

In a further aspect, the invention concerns with a method of silencing the expression of a target sequence within the genome of a plant or within the genome of a plant infecting pathogen present in the cell prior to the following manipulations, which method comprises the steps of:- (a) providing a first plant capable of regenerating; (b) hybridizing said first plant with a second plant transformed with:- (i) a first DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, said construct further comprising at least one plant promoter and at least one plant terminator sequence operably linked to said sequence; and with (ii) a second DNA construct comprising a T7 promoter sequence (pT7), a targeting sequence downstream to said pT7 and a 3' non-translated terminator sequence operably linked to said targeting sequence, said construct optionally further comprising additional regulatory elements operably linked to said targeting sequence, said plant being referred to as a double-transformed plant; and (c) selecting plants obtained by the hybridization of step (b), in which the expression of said target sequence is substantially silenced.

Alternatively, the method of silencing the expression of a target sequence within the genome of a plant according to the invention or with the genome of a plant infecting pathogen present in the cell prior to the following manipulations may comprise the steps of:- (a) providing a first plant comprising said target sequence, which plant is capable of regenerating; (b) hybridizing said first plant with a second plant transformed with a DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, said construct further comprising a plant promoter and a plant terminator sequence operably linked to said T7-pol, a T7 promoter (pT7) or a functional fragment thereof, a targeting sequence downstream to said pT7, and at least one additional promoter sequence operably linked to said targeting sequence and; (c) selecting plants obtained by the hybridization of step (b), wherein the expression of said target sequence is substantially silenced.

In any case, the targeting sequence within the system will substantially corresponds to the target sequence or to a fragment thereof and the target sequence may correspond to:- (a) a gene encoding a protein or a peptide product, the silencing of which is desired; (b) a non-coding nucleic acid sequence, which, under normal conditions, promotes the expression of an essential coding sequence; (c) a nucleic acid sequence which corresponds to (a) or to (b) or to a fragment thereof, within the scope of degeneracy of the genetic code; or (d) a nucleic acid sequence which hybridizes with the sequence according to (a), to (b), or to (c) or with fragments thereof, which hybridization is carried out under conditions which allow such hybridization to occur.

Finally, the invention concerns with a method of identifying a nucleic acid of interest within a plant's genome wherein the nucleic acid of interest encodes a pre-defined plant phenotype, which process comprises the steps of:- (a) providing a first plant comprising within its genome said nucleic acid of interest; (b) transforming said first plant with a second plant transformed with:- (i) a first DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, said construct further comprising at least one plant promoter and at least one plant terminator sequence operably lined to said sequence; and with (ii) a second DNA construct comprising a T7 promoter sequence, a random nucleic acid sequence downstream to said T7 promoter, and a 3' non-translated terminator sequence operably linked to said random nucleic acid sequence, said construct optionally further comprising additional regulatory elements operably linked to said nucleic acid of interest, said transformation thus provides a population of transgenic plants; (b) selecting from the population obtained in step (a) transformed plants/plant cells in which the pre-defined phenotype is substantially silenced; and (c) employing said random nucleic acid sequence within the genome of the transformed plants selected in step (c) as a probe in screening genomic DNA and cDNA libraries of said first plant, thereby identifying the gene comprising said random nucleic acid sequence which gene is responsible for said pre-defined phenotype.

Alternatively, the method of identifying a nucleic acid of interest within a plant's genome wherein said nucleic acid of interest encodes a pre-defined plant phenotype, may comprise the steps of:- (a) providing a first plant comprising within its genome said nucleic acid of

interest; (b) transforming said first plant or with a second plant transformed with a DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, said construct further comprising at least one plant promoter sequence and at least one plant terminator sequence operably linked to said T7-pol, said DNA construct further comprising a T7 promoter sequence or a functional fragment thereof, a random nucleic acid sequence downstream to said T7 promoter, and a 3' non-translated terminator sequence operably linked to said random nucleic acid sequence; and (c) selecting from the plants obtained in step (b) those transformed plants in which the pre-defined phenotype is substantially silenced; and (d) employing said random nucleic acid sequence within the genome of the transformed plants selected in step (c) as a probe in screening genomic DNA or cDNA libraries of said first plant, thereby identifying the gene comprising said random nucleic acid sequence, which gene is responsible for said pre-defined phenotype.

Evidently, any further uses of the expression-silencing system, the process for the transformation of a selected cell with said system, the transgenic plant introduced with the system of the invention and the different methods of the invention, are also within the scope of the invention.

The invention will now be described in an illustrative manner and it is to be understood that the terminology which will be used is intended to be in the nature of the words of description rather than of limitation.

Obviously, many modifications and variations of the present invention are possible in light of the above teaching. It is therefore, to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

EXAMPLES

Example 1 - General methodology

DNA sequences were isolated from plants, from bacteriophage T7 and from the virus tobacco mosaic virus (TMV) and propagated in a suitable plasmid (e.g. pBluescript, pCR2.1) in *E.coli* JM109 by a standard procedure [Sambrook J., *et al.* Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Press (1989); Ausubel F.M., *et al.* Current

Protocols in Molecular Biology. John Wiley & Sons Inc. (1995)]. Alternatively, DNA sequences to be transferred to plants were provided by the binary plasmids (such as the pBI101). The DNA sequences utilized were the plant promoter p35S, the bacteriophage gene for T7 RNA polymerase (T7-pol), the plant terminator NOS, the bacteriophage terminator (T7-terminator), the translation enhancer from TMV (Ω) and the coding sequence of the bacterial gene for β -glucuronidase (GUS).

Cloning of T7-pol and GUS

The gene for T7-pol was 5'-fused with the Ω -translation-enhancer element from TMV and the SV-40 element, NLS, directing protein transport to the nucleus. This construct was placed between a CaMV-35S promoter (p35S) and a NOS terminator and was designated-35S-T7-pol. Two constructs of GUS were prepared, both 5'-fused to Ω : one construct p35S-GUS was placed between p35S and the NOS terminator, and the other (pT7-GUS) between pT7 and, assuming that T7-pol may not recognize plant termination signals, two terminators: the plant NOS terminator and the bacteriophage T7 terminator. All constructs also carried the NPTII gene for Km resistance, and were transferred into the binary plasmids pGA643 and pBI101 [Vardi E., *et al.* Proc. Natl. Acad. Sci. USA 90: 7513-7517 (1993)], which provided border sequences for integration into the plant's genome and cassettes for a selectable marker in plants (kanamycin resistance). Figure 1A and 1B show the constructs obtained. Figure 1C represents a positive control wherein the cassette introduced into the binary plasmid pBI101 carries the GUS coding sequences between p35S and the NOS terminator.

GUS assay

Gus activity was assayed either histochemically or by fluorometric determination of the production of 4-methylumbelliferone (4-MU) from its substrate 4-methylumbelliferyl glucuronide (MUG, sigma) according to the methodology described [Jefferson R.A., Plant Mol. Biol. Rep. 5:387-405 (1987)].

RNA assay

All assays were carried out with p35S-T7-pol/pT7-GUS plants and with 35S-GUS plants as controls. Since the absence of GUS expression could have been attributed to the

expression of an inactive T7-pol, or to its inability to move to the nucleus and affect transcription, initial transcription was tested first by nuclear run-on assays. As indicated in Figure 3, GUS transcripts were driven from p35S as well as from pT7. The level of GUS transcription from pT7 was comparable to that of the expressed T7-pol and NPTII genes (driven by p35S and pNOS, respectively), but higher than the internal control of the ubiquitin gene under its own native promoter. As expected, the control p35S-GUS plants readily transcribed GUS.

RNase-protection assays, however, indicated that while T7-pol-mRNA and actin-mRNA are present in the 35S-T7-pol/pT7-GUS plants, GUS-mRNA is absent. GUS-mRNA and the internal control actin-mRNA were both detected in the control p35S-GUS plants (Fig. 4). Silencing of GUS expression in a plant T7-pol/pT7 system therefore occurs at a post-transcriptional stage.

Nuclear run-on assay

The procedure was carried out essentially as described by Cox and Goldberg [Cox K.H., and Goldberg R.H, in Plant Molecular Biology. A Practical Approach (Shaw C.H. Ed) Washington DC IRL Press pp 1-35]. Reduction of the starch content was found to be essential for a good preparation. Therefore, plants were stored in the dark for 48 hr prior to nucleic isolation. Nuclei were finally separated on 40-76% percol gradients and stored as 100 µl aliquots at -80°C.

In order to enable quantitative comparisons, relevant plasmids (1 µg per 1000 bp) were boiled and quickly cooled, and the denatured plasmid was slot-blotted onto a nitrocellulose membrane. A regular Southern-type procedure was then performed with the nuclear RNA preparation as a probe.

RNase protection assay

GUS mRNA electrophoresed to about the same position as the 18S rRNA. To avoid background problems, RNase protection was therefore preferred to Northern-blot hybridization.

RNase protection assays were carried out essentially according to the manufacturer's protocol (Ribonuclease Protection Kit Ambion). Three probes were prepared for the RNase protection assays: An internal control actin probe (474 bases) was made by PCR amplification of a segment of the actin cDNA between bases 4282-4736 from tobacco DNA (GenBank #X63603). The amplified product was cloned into the plasmid Bluescript KS (Stratagene). The antisense probe was transcribed from the T3 promoter of the linearized recombinant plasmid (BamHI). The GUS probe was prepared by cleaving out an XbaI-EcoRI fragment from a GUS carrying plasmid (pBI221, Clontech) and subcloning it into the plasmid Bluescript. A 760bp antisense probe was prepared by transcribing the MluI-linearized plasmid from the T3 promoter. The probe for T7-pol was a BamHI-EcoRI fragments subcloned into Bluescript from Tabor and Richardson's plasmid pGP1-2. The antisense probe (240bp) was transcribed from the T7 promoter of the NdeI-linearized plasmid.

Example 2 - Plant transformation and silencing of GUS expression

Agrobacterium tumefaciens carrying a compatible disarmed Ti plasmid (e.g. pEHA101) was transformed with one of the engineered binary plasmids by triparental mating [An G., Methods Enzymol. 153:292-305 (1987)], or by electroporation [Li-Chin-Ho *et al.* Plant Physiology and Biochemistry 35:959-968 (1997)] with GenePulser II (performed according to the manufacturer's instructions, Biorad).

Agrobacterium-mediated transformation was carried out, and homozygous plants were selected at the R2 stage as described previously [Vardi E., *et al.* (1993) *ibid.*]. In particular, tobacco and tomato leaf discs were inoculated with the transformed *A. tumefaciens* according to standard procedure [An G. (1987) *ibid.*]. Agro-inoculated leaf discs were placed on the following medium: MS salts (4.71 gr/L) [Murashige T. and Skoog F. Physiol. Plant. 15:485-497 (1962)], sucrose (20 gr/L), maniol (10 gr/L), Nobel Agar (10 gr/L), scatin (2 mg/L), IAA (indole acetic acid 0.1 Gr/L), pH 5.8. After 48 hrs in this

medium, the leaf discs were transferred into a fresh medium further containing kanamycin (300 µg/ml) and carbenicillin (300 µg/ml) which was replaced every 10 days. Callus developed from the leaf discs (20-30 days from Agro-inoculation) was transferred to the same initial medium however containing 400 µg/ml kanamycin. Shoots developing from the callus were transferred individually for root development to a medium containing: MS salts (4.71 g/L), sucrose (30 gr/L), Nohel Agar (10 gr/L). Rooted shoots were then potted and transferred to the greenhouse to grow into mature flowering plants.

As an alternative procedure, plants may be introduced with the relevant vectors also by biolistic methods [Bionard protocols] by bombarding beads coated with the pertinent DNA into plant tissues.

As an alternative to the selection of the transformed plants using a selection marker, efficient selection may be obtained based on PCR identification of the transgene or by histochemical assays for GUS expression, as an alternative or in addition to the selectable marker.

Plants transformed with the construct shown in Fig 1A, which were capable of expressing (transcription and translation) GUS, were hybridized with plants transformed with the cassette comprising pT7, Ω , GUS and two terminators (Fig. 1B). The resultant double-transformed plant expressed T7-pol (Fig 2), transcribed GUS (Fig. 3) but did not produce GUS mRNA (Fig. 4) and thus was unable to express GUS protein (Table 2), which exhibits the silencing of the expression of GUS at the post-transcriptional level. Importantly, the expression of GUS was silenced in all the resulting transgenic plants.

Example 3 - Preparation of progeny silenced plants via pollination (silencing in trans)

Transgenic R0 tobacco plants carrying the p35S-RNA-pol construct were crossed with similar plants carrying the pT7-GUS construct (see Fig. 1 for a diagram of the constructs). The hybrid plants were self-pollinated and progeny were selected for several generations. At all stages plants were PCR-analyzed for both T7-pol and GUS, and only plants carrying both genes were selected. Then, a double transformed 35S-T7-pol/pT7-GUS plant was pollinated by an expressing 35S-GUS control plant. Three of the progeny plants out of 18 were found to carry all three genes (35S-T7-pol, pT7-GUS and 35S-GUS) as determined by PCR using a promoter-specific and a gene-specific primers for each case. None of these

triple-transformed plants exhibited GUS activity either by histochemical staining (data not shown) or by measuring GUS activity in plant's extracts (Table 1). Hence, once the T7-derived silencing machinery was set in motion it was capable of silencing an already active pertinent gene. The evoked silencing mechanism was therefore not a peculiarity of the foreign T7 system but carried relevance to silencing of the gene under a "native" plant promoter.

Many of the 35S-T7-pol/pT7-GUS transgenic plants, belonging to all lines, expressed T7-pol, as indicated by Western-blot analyses. Seedlings of these plants (2,100, belonging to 21 lines) were tested for GUS expression histochemically, or by assaying GUS activity in plant extracts.

T7-driven GUS activity could not be found in these plants. Lack of GUS expression was observed in the double-transformed plants regardless of the level of expression of T7-pol (Table 1). Only in two plants GUS staining was observed in pollen grains (Figure 2) and callus (data not shown). GUS activity was, however, fully silenced in the leaves of these 2 plants which was corroborated also by nuclear run-on and RNase protection assays.

Table 1 - GUS enzymatic activity

The transgenic plant	No. of tested plants	GUS activity (average) nmole 4-MU/h/mg protein
Non-transformed (SR1)	5	0.7
35S-GUS	5	272±71
T7-GUS	5	0.8
35S-T7-pol	5	0.6
35S-T7-pol/T7-GUS ^a	5	0.7
35S-T7-pol/T7-GUS/35S-GUS ^b	3	0.6

^a double-transformed plants

^b triple-transformed plants

Example 4 - Silencing of expressing a target gene via grafting

Transgenic RO tobacco plants carrying the p35S-RNA-pol construct were crossed with similar plants carrying the pT7-GUS construct (Fig. 1). The hybrid plants were self

pollinated and progeny were selected for several generations. At all stages plants were PCR-analyzed for both T7-pol and GUS, and only plants carrying the both genes were selected. Then, a scion from an expressing 35S_GUS plant was grafted upon the double-transformed, GUS-silenced plants. Shoots growing from the grafted scions were examined for GUS expression histochemically. Three out of the 6 plants in this experiment were silenced for GUS. Hence, in some cases, once the T7-derived silencing machinery was set in motion, it was capable of signal silencing to an already active pertinent gene across a graft.

Example 5 - Conferring plants with resistance to a plant pathogen (TMV)

Resistance to TMV in plants carrying the expression silencing system of the invention which included a TMV originated sequence (Ω) downstream to pT7 was also examined. Accordingly, several of the double-transformed plants were inoculated with TMV (10 μ g/ml in 0.01M phosphate buffer). Seven days post-inoculation, five leaf discs (6 mm in diameter) were cut of randomly from each plant and identically processed for ELISA with antibodies raised against the purified virus. The results presented in Table 1 show that all the double-transformed plant became partially or fully resistant to TMV (Table 2).

These results and the results presented for the silencing of GUS expression clearly indicate that the expression silencing system of the invention may carry a variety of targeting genes, homologous or heterologous, thereby silencing a broad spectrum of genes of interest.

Table 2 - ELISA readings for TMV in tobacco plants

Type of plant	Absorbance at 405 nm
Non-infected	0.038
Non-transgenic, TMV infected	0.614
Double transformant 1	0.208
Double transformant 2	0.022
Double transformant 3	0.250
Double transformant 4	0.087
Double transformant 5	0.015
Triple transformant 1	0.045
Triple transformant 2	0.008
Triple transformant 3	0.042

CLAIMS**1. An expression silencing system comprising**

- a) a first DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or to a functional equivalent or fragment thereof which sequence carries an NLS sequence, and further comprising at least one promoter and at least one terminator sequence operably linked to said T7-pol; and
- b) a second DNA construct comprising a T7 promoter sequence (pT7) or a functional fragment thereof, at least one targeting sequence downstream to said pT7 and at least one 3' non-translated terminator sequence operably linked to said targeting sequence;

which system is capable, upon introduction thereof into a cell, of rendering the expression at the RNA level of a target sequence in said cell, in a tissue or organ regenerated from said cell or in a progeny thereof, substantially silenced, by causing the substantial disappearance of the RNA or RNA transcript carrying said sequence or a functional part thereof.

- 2. A protein expression silencing system comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, which construct further comprises at least one promoter and at least one terminator sequence operably linked to said T7-pol, a T7 promoter (pT7) or a functional equivalent or fragment thereof, at least one targeting sequence downstream to said the pT7, and at least one additional terminator sequence operably linked to said targeting sequence, said system being capable, upon introduction thereof into a cell, of rendering the expression at the RNA level of a target sequence in said cell, in a tissue or organ regenerated from said cell or in a progeny thereof, substantially silenced, by causing the substantial disappearance of the RNA or RNA transcript carrying said sequence.
- 3. The expression silencing system as claimed in claim 1 or claim 2, wherein said cell, in which the expression at the RNA level is substantially silenced is an eukaryotic

cell or a prokaryotic cell selected from a plant cell, a mammalian cell, a bacterium, a yeast, their pathogens, or any suitable tissue culture cell.

4. The expression-silencing system as claimed in claim 1 or claim 2, wherein said regenerated organ is a flowering differentiated plant regenerated from said cell.
5. The expression silencing system as claimed in claim 1 or claim 2, wherein said at least one targeting sequence substantially identical or homologous to at least part of said target sequence.
6. The expression silencing system as claimed in claim 5, wherein said target sequence corresponds to:-
 - a) a gene encoding a protein or a peptide product, the silencing of which is desired;
 - b) a non-coding nucleic acid sequence, which, under normal conditions, promotes the expression of an essential coding sequence;
 - c) a nucleic acid sequence which corresponds to (a) or to (b) or to a fragment thereof, within the scope of degeneracy of the genetic code; or
 - d) a nucleic acid sequence which hybridizes with the sequence according to (a), to (b), or to (c) or with fragments thereof, which hybridization is carried out under conditions which allow such hybridization to occur.
7. The expression silencing system as claimed in claim 6, wherein said gene encodes a plant protein or peptide product or a protein or peptide product of a plant pathogen.
8. The expression silencing system as claimed in claim 7, wherein said protein or peptide product of a plant pathogen is plant virus, a bacterium or a fungus capable of infecting said plant.
9. The expression silencing system as claimed in claim 7, wherein said gene encodes the GUS protein.
10. The expression silencing system as claimed in claim 6, wherein said gene encodes a human protein or peptide product or a protein or peptide product of a human pathogen.

11. The expression silencing system as claimed in claim 6, wherein said non-coding sequence is a regulatory element sequence which, under normal conditions, promotes the expression of a coding sequence.
12. The expression silencing system as claimed in claim 11, wherein said target sequence is the TMV non-coding sequence Ω .
13. The expression silencing system as claimed in claim 5, optionally further comprising additional regulatory elements.
14. The expression silencing system as claimed in claim 5, wherein said NLS sequence is the SV-40 NLS sequence.
15. The expression silencing system as claimed in claim 5, wherein said promoter sequence is the plant promoter p35S.
16. The expression silencing system as claimed in claim 1 or claim 2, wherein any or both of said terminators is the NOS terminator or a functional equivalent or fragment thereof, the β -1,3-glucanase terminator or any other suitable terminator capable of terminating the transcription of a nucleic acid sequence and of the addition of polyadenylated ribonucleotides to the 3' end of the primary transcript of said nucleic acid.
17. The expression silencing system as claimed in claim 1 or claim 2, wherein said pT7 corresponds to the promoter sequence of the bacteriophage T7 or functional analogues thereof, which promoter is capable of initiating transcription of said at least one targeting sequence downstream thereto.
18. The expression silencing system as claimed in claim 1 or claim 2, comprising the T7 terminator and the NOS terminator operably linked to said targeting sequence.
19. The expression silencing system as claimed in claim 1, wherein said first and second DNA constructs are substantially as shown in Figures 1A and 1B, respectively.
20. A process for the transformation of a plant with a gene-silencing system which process comprises:-
- a) transforming plant cells with:-

- i) a first DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof, at least one plant promoter and at least one plant terminator sequence operably linked to said T7-pol;
- and with
- ii) a second DNA construct comprising a T7 promoter sequence or a functional fragment thereof, a targeting sequence downstream to said T7 promoter, and at least one 3' non-translated terminator sequence operably linked to said targeting sequence, said construct optionally further comprising other additional regulatory elements operably linked to said targeting sequence;
- b) selecting the plant cells transformed with at least one DNA construct according to (a) and regenerating said selected cells to provide a differentiated flowering plant; and
- c) hybridizing a plant transformed with said first DNA construct with a plant transformed with said second DNA construct, which first plant and second plant are obtained in (b), said hybridization thus providing a double-transformed plant in which the expression of a target sequence is substantially suppressed.
21. A process for the transformation of plant with a gene-silencing system, which process comprises:-
- a) transforming plant cells with a DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, said construct further comprising at least one plant promoter sequence and at least one plant terminator sequence operably linked to said polymerase gene, a T7 promoter sequence (pT7) or a functional fragment thereof, a targeting sequence downstream to said pT7, and at least one additional terminator sequence operably linked to said targeting sequence, which DNA construct is capable, upon transformation thereof into a plant, of rendering the expression of a target sequence in said plant or in its progeny, substantially silenced; and

- b) selecting plant cells transformed with said DNA construct according to (a) and regenerating said selected cells to provide a differentiated flowering plant.
22. The process as claimed in claim 20 or claim 21, wherein said targeting sequence substantially corresponds to said target sequence or to a fragment thereof.
23. The process as claimed in claim 22, wherein said target sequence corresponds to:-
- a) a gene encoding a protein or a peptide product, the silencing of which is desired;
 - b) a non-coding nucleic acid sequence, which, under normal conditions, promotes the expression of an essential coding sequence;
 - c) a nucleic acid sequence which corresponds to (a) or to (b) or to a fragment thereof, within the scope of degeneracy of the genetic code; or
 - d) a nucleic acid sequence which hybridizes with the sequence according to (a), to (b), or to (c) or with fragments thereof, which hybridization is carried out under conditions which allow such hybridization to occur.
24. A method for producing a transgenic plant carrying a substantially silent target sequence, by hybridizing a plant carrying and expressing said target sequence with a transformed plant obtained by the process of claim 22.
25. A method for producing a transgenic plant carrying a substantially silent target sequence, by grafting a plant, or parts thereof, carrying and expressing said silent target sequence on a transformed plant obtained by the process of claim 22.
26. A transgenic plant or its progeny obtained by the method of claim 24 or claim 25, in which the expression of said target sequence is substantially suppressed.
27. A method of silencing the expression of a target sequence within the genome of a plant or within the genome of a plant infecting pathogen present in said cell prior to the following manipulation, which method comprises the steps of:
- a) providing a first plant capable of regenerating;
 - b) hybridizing said first plant with a second plant double transformed with:-
 - i) a first DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, said construct

further comprising at least one plant promoter and at least one plant terminator sequence operably lined to said sequence;

and with

ii) a second DNA construct comprising a T7 promoter sequence (pT7), a targeting sequence downstream to said pT7 and a 3' non-translated terminator sequence operably linked to said targeting sequence, said construct optionally further comprising additional regulatory elements operably linked to said targeting sequence; and

c) selecting those plants obtained by the hybridization of step (b), in which the expression of said target sequence is substantially silenced.

28. A method of silencing the expression of a target sequence within the genome of a plant or within the genome of a plant infecting pathogen present in said cell prior to the following manipulation, which method comprises the steps of:-

a) providing a first plant comprising said target sequence, said plant being capable of regenerating;

b) hybridizing said first plant with a second plant transformed with a DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, said construct further comprising a plant promoter and a plant terminator sequence operably linked to said T7-pol, a T7 promoter (pT7) or a functional fragment thereof, a targeting sequence downstream to said pT7, and at least one additional promoter sequence operably linked to said targeting sequence; and

c) selecting those plants obtained by the hybridization of step (b), in which the expression of said target sequence is substantially silenced.

29. A method as claimed in claim 27 or claim 28, wherein said targeting sequence substantially corresponds said target sequence or to a fragment thereof.

30. The method as claimed in claim 28, wherein said target sequence corresponds to:-

a) a gene encoding a protein or a peptide product, the silencing of which is desired;

- d) employing said random nucleic acid sequence within the genome of transformed plants selected in step (c) as a probe in screening genomic DNA and cDNA libraries of said first plant, thereby identifying the gene comprising said random nucleic acid sequence which gene is responsible for said pre-defined phenotype.

32. A method of identifying a nucleic acid of interest within a plant's genome wherein said nucleic acid of interest encodes a pre-defined plant phenotype, which process comprises the steps of:-

- a) providing a first plant comprising within its genome said nucleic acid of interest;
- b) transforming said first plant with a second plant transformed with a DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) or a functional equivalent or fragment thereof which sequence carries an NLS sequence, said construct further comprising at least one plant promoter sequence and at least one plant terminator sequence operably linked to said T7-pol, said DNA construct further comprising a T7 promoter sequence or a functional fragment thereof, a random nucleic acid sequence downstream to said T7 promoter, and a 3' non-translated terminator sequence operably linked to said random nucleic acid sequence;
- c) selecting from the plants obtained in step (b) transformed plants in which the pre-defined phenotype is substantially silenced; and
- d) employing said random nucleic acid sequence within the genome of the transformed plants selected in step (c) as a probe in screening genomic DNA or cDNA libraries of said first plant, thereby identifying the gene comprising said random nucleic acid sequence, which gene is responsible for said pre-defined phenotype.

1/3

P35S	Ω	NLS	T7 RNA Polymerase	NOS terminator
------	----------	-----	-------------------	----------------

Fig. 1A

PT7	Ω	GUS	T7 RNA Polymerase	NOS terminator
-----	----------	-----	-------------------	----------------

Fig. 1B

P35S	Ω	GUS	NOS terminator
------	----------	-----	----------------

Fig. 1C

2/3




Fig. 2




Fig. 3

3/3




Fig. 4A



Fig. 4B

[illegible]

Declaration and Power of Attorney

Page 2

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

<u>Provisional Application No.</u>	<u>Filing Date</u>	<u>Status</u>
N/A		

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which become available between the filing date(s) of such prior Application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
PCT/IL00/00029	16 January 2000	pending

And I hereby appoint

20 John P. White (Reg. No. 28,768); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Robert T. Maldonado (Reg. No. 38,232); Paul Teng (Reg. No. 40,837); Richard F. Jaworski (Reg. No. 33,515); Pedro C. Fernandez (Reg. No. 41,741); Gary J. Gershik (Reg. No. 39,992); Jane M. Love (Reg. No. 42,812); Spencer H. Schneider (Reg. No. 45,923); Alan D. Morrison (Reg. No. 37,399); Alan Miller (Reg. No. 42,889); Christopher M. Ries (Reg. No. 45,799) and Frank Bruno (Reg. No. 46,583)

and each of them, all c/o Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Please address all communications, and direct all telephone calls, regarding this application to:

John P. White

Reg. No. 28,678

Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor Ilan Sela

Inventor's signature

Israel

Date of signature 23.10.01

Residence 113 Ha'banim Street, Nes Ziona 74037 Israel

Post Office Address same as residence address

Full name of joint inventor (if any) Sylvia Zeitoune-Simovich

Inventor's signature

Israel

Date of signature 21-10-01

Residence 14 Cremieux Street, 64259 Tel Aviv, Israel

Post Office Address same as residence address

Full name of joint
inventor (if any) _____

Inventor's signature

Citizenship.

Date of signature

Residence.

Post Office Address.